A cash infusion from Nestle and an uptick in online consumer sales has buoyed ChromaDex as executives say the brand is on course to be in plus EBITDA territory by the end of fiscal 2022.
America’s nicotinamide riboside (NR) maker Chromadex is eyeing omnichannel retail in China and is confident of achieving the ‘blue-hat’ health foods registration status – required for normal trade of health foods in China – in the next 24 months or less....
China’s consumers are increasingly aware of how nicotinamide adenine dinucleotide (NAD+) plays a role in health, and Chromadex believes this presents opportunities for its flagship product Tru Niagen.
ChromaDex has been expanding steadily in Asia-Pacific, first launching its signature nicotinamide riboside (NR) supplement, TRU NIAGEN, in Hong Kong and Macau last year, followed by Singapore early this year and most recently, New Zealand.
Nutraceutical firm ChromaDex will launch its TRU NIAGEN supplement in New Zealand next month via its exclusive distributor, local supplement brand Matakana Superfoods.